Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

S.B. Winther; G. Liposits; H. Skuladottir; E. Hofsli; C.-H. Shah; L.Ø. Poulsen; J. Ryg; P. Österlund; Å. Berglund; C. Qvortrup; B. Glimelius; H. Sorbye; P. Pfeiffer

doi:10.1016/s2468-1253(19)30041-x

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

S.B. Winther, G. Liposits, H. Skuladottir, E. Hofsli, C.-H. Shah, L.Ø. Poulsen, J. Ryg, P. Österlund, Å. Berglund, C. Qvortrup, B. Glimelius, H. Sorbye, P. Pfeiffer

Research output: Contribution to journal › Article › Scientific › peer-review

43 Citations (Scopus)

Original language	English
Pages (from-to)	376-388
Journal	The lancet gastroenterology and hepatology
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/s2468-1253(19)30041-x
Publication status	Published - 2019
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s2468-1253(19)30041-x

Cite this

Winther, S. B., Liposits, G., Skuladottir, H., Hofsli, E., Shah, C.-H., Poulsen, L. Ø., Ryg, J., Österlund, P., Berglund, Å., Qvortrup, C., Glimelius, B., Sorbye, H., & Pfeiffer, P. (2019). Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The lancet gastroenterology and hepatology, 4(5), 376-388. https://doi.org/10.1016/s2468-1253(19)30041-x

@article{0a31ce921c9941c6a655af35efd61d9e,

title = "Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial",

author = "S.B. Winther and G. Liposits and H. Skuladottir and E. Hofsli and C.-H. Shah and L.{\O}. Poulsen and J. Ryg and P. {\"O}sterlund and {\AA}. Berglund and C. Qvortrup and B. Glimelius and H. Sorbye and P. Pfeiffer",

year = "2019",

doi = "10.1016/s2468-1253(19)30041-x",

language = "English",

volume = "4",

pages = "376--388",

number = "5",

}

Winther, SB, Liposits, G, Skuladottir, H, Hofsli, E, Shah, C-H, Poulsen, LØ, Ryg, J, Österlund, P, Berglund, Å, Qvortrup, C, Glimelius, B, Sorbye, H & Pfeiffer, P 2019, 'Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial', The lancet gastroenterology and hepatology, vol. 4, no. 5, pp. 376-388. https://doi.org/10.1016/s2468-1253(19)30041-x

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. / Winther, S.B.; Liposits, G.; Skuladottir, H. et al.
In: The lancet gastroenterology and hepatology, Vol. 4, No. 5, 2019, p. 376-388.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

AU - Winther, S.B.

AU - Liposits, G.

AU - Skuladottir, H.

AU - Hofsli, E.

AU - Shah, C.-H.

AU - Poulsen, L.Ø.

AU - Ryg, J.

AU - Österlund, P.

AU - Berglund, Å.

AU - Qvortrup, C.

AU - Glimelius, B.

AU - Sorbye, H.

AU - Pfeiffer, P.

PY - 2019

Y1 - 2019

U2 - 10.1016/s2468-1253(19)30041-x

DO - 10.1016/s2468-1253(19)30041-x

M3 - Article

SN - 2468-1253

VL - 4

SP - 376

EP - 388

JO - The lancet gastroenterology and hepatology

JF - The lancet gastroenterology and hepatology

IS - 5

ER -

Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ et al. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The lancet gastroenterology and hepatology. 2019;4(5):376-388. doi: 10.1016/s2468-1253(19)30041-x